Skip to content
Disclosery

Caligan Partners LP

Follow

13F filer, CIK 1727492, NEW YORK, NY

Caligan Partners LP reported $2,125,706,950 across 28 holdings for the quarter ended 2026-06-30, in a 13F-HR filed 2026-08-14. Its ten largest share positions make up 82.94% of the portfolio.

Filed (acceptance time not in the bulk data set), ingested 13F-HR 0001420506-26-001809

Period
2026-06-30
Reported value
$2.13B
Holdings
28
Top 10 weight
82.94%
New
5
Sold out
5

Largest buys vs the previous quarter

SecurityShares changeApprox. value
RVMDadded+308,987$57.9M
IMCRnew+1,381,317$43.9M
VRDNnew+2,193,981$40.3M
AURAadded+4,068,384$28.9M
AVTXadded+1,528,843$28.3M

Ranked by the share change valued at this quarter's implied price (value over shares in the 13F). A position sold out is valued at the previous quarter's price, its last report.

Largest sells vs the previous quarter

SecurityShares changeApprox. value
MLYSexited-2,772,654-$75.1M
SYREexited-878,127-$44.3M
MBXreduced-648,590-$35.8M
XENEreduced-503,083-$30.4M
MAZEexited-614,962-$18.4M

Ranked by the share change valued at this quarter's implied price (value over shares in the 13F). A position sold out is valued at the previous quarter's price, its last report.

Holdings, Q2 2026

Share positions as resolved from 13F-HR 0001420506-26-001809, largest first. % of portfolio is the value over $2,072,698,946, the sum of the share positions whose value is usable for ratios (method).

SecurityHistorySharesValue% of portfolioChangeLatest eventTimeline
LQDALIQUIDIA CORPORATIONQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q3: 8,118,592 shares; 2024Q4: 8,118,592 shares; 2025Q1: 8,118,592 shares; 2025Q2: 8,118,892 shares; 2025Q3: 8,118,892 shares; 2025Q4: 8,118,892 shares; 2026Q1: 8,118,892 shares; 2026Q2: 8,118,892 shares 8,118,892$647M31.23%0Timeline
RVMDREVOLUTION MEDICINES INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q3: not reported; 2024Q4: not reported; 2025Q1: 465,000 shares; 2025Q2: 636,835 shares; 2025Q3: 1,064,249 shares; 2025Q4: 1,283,900 shares; 2026Q1: 1,652,808 shares; 2026Q2: 1,961,795 shares 1,961,795$367M17.73%+308,987Timeline
ABVXABIVAX SAQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q3: not reported; 2024Q4: 752,167 shares; 2025Q1: 1,269,119 shares; 2025Q2: 1,674,400 shares; 2025Q3: 1,451,924 shares; 2025Q4: 1,451,924 shares; 2026Q1: 1,461,924 shares; 2026Q2: 1,557,924 shares 1,557,924$208M10.02%+96,000Timeline
PCVXVAXCYTE INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q3: not reported; 2024Q4: not reported; 2025Q1: not reported; 2025Q2: not reported; 2025Q3: not reported; 2025Q4: 1,704,815 shares; 2026Q1: 2,060,719 shares; 2026Q2: 2,188,636 shares 2,188,636$127M6.14%+127,917Timeline
EXELEXELIXIS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q3: 1,525,730 shares; 2024Q4: 1,525,730 shares; 2025Q1: 1,525,730 shares; 2025Q2: 1,525,730 shares; 2025Q3: 1,525,730 shares; 2025Q4: 1,553,262 shares; 2026Q1: 1,553,262 shares; 2026Q2: 1,553,262 shares 1,553,262$84.5M4.08%0Timeline
TNGXTANGO THERAPEUTICS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q3: not reported; 2024Q4: not reported; 2025Q1: not reported; 2025Q2: not reported; 2025Q3: not reported; 2025Q4: 3,729,895 shares; 2026Q1: 2,408,798 shares; 2026Q2: 2,500,103 shares 2,500,103$78.2M3.77%+91,305Timeline
AVTXAVALO THERAPEUTICS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q3: not reported; 2024Q4: not reported; 2025Q1: not reported; 2025Q2: not reported; 2025Q3: 833,333 shares; 2025Q4: 881,533 shares; 2026Q1: 1,635,023 shares; 2026Q2: 3,163,866 shares 3,163,866$58.5M2.82%+1,528,843Timeline
XENEXENON PHARMACEUTICALS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q3: not reported; 2024Q4: not reported; 2025Q1: not reported; 2025Q2: not reported; 2025Q3: 444,565 shares; 2025Q4: 549,665 shares; 2026Q1: 1,393,027 shares; 2026Q2: 889,944 shares 889,944$53.7M2.59%-503,083Timeline
ADMAADMA BIOLOGICS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q3: not reported; 2024Q4: not reported; 2025Q1: not reported; 2025Q2: not reported; 2025Q3: 2,636,609 shares; 2025Q4: 3,012,508 shares; 2026Q1: 4,756,511 shares; 2026Q2: 5,725,007 shares 5,725,007$47.9M2.31%+968,496Timeline
LBRXLB PHARMACEUTICALS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q3: not reported; 2024Q4: not reported; 2025Q1: not reported; 2025Q2: not reported; 2025Q3: not reported; 2025Q4: not reported; 2026Q1: 1,438,070 shares; 2026Q2: 1,438,070 shares 1,438,070$46.7M2.25%0Timeline
IMCRIMMUNOCORE HLDGS PLCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q3: not reported; 2024Q4: not reported; 2025Q1: not reported; 2025Q2: not reported; 2025Q3: not reported; 2025Q4: not reported; 2026Q1: not reported; 2026Q2: 1,381,317 shares 1,381,317$43.9M2.12%newTimeline
VRDNVIRIDIAN THERAPEUTICS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q3: not reported; 2024Q4: not reported; 2025Q1: not reported; 2025Q2: not reported; 2025Q3: not reported; 2025Q4: not reported; 2026Q1: not reported; 2026Q2: 2,193,981 shares 2,193,981$40.3M1.94%newTimeline
VORVOR BIOPHARMA INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q3: not reported; 2024Q4: not reported; 2025Q1: not reported; 2025Q2: not reported; 2025Q3: not reported; 2025Q4: 925,067 shares; 2026Q1: 1,925,066 shares; 2026Q2: 1,925,066 shares 1,925,066$35.4M1.71%0Timeline
SABSSAB BIOTHERAPEUTICS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q3: not reported; 2024Q4: not reported; 2025Q1: not reported; 2025Q2: not reported; 2025Q3: not reported; 2025Q4: not reported; 2026Q1: 7,967,207 shares; 2026Q2: 7,967,207 shares 7,967,207$31.1M1.5%0Timeline
IVAINVENTIVA SAQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q3: not reported; 2024Q4: not reported; 2025Q1: not reported; 2025Q2: not reported; 2025Q3: not reported; 2025Q4: 2,000,000 shares; 2026Q1: 4,974,906 shares; 2026Q2: 8,163,191 shares 8,163,191$30.9M1.49%+3,188,285Timeline
AURAAURA BIOSCIENCES INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q3: not reported; 2024Q4: not reported; 2025Q1: not reported; 2025Q2: 200,000 shares; 2025Q3: 227,174 shares; 2025Q4: not reported; 2026Q1: 229,864 shares; 2026Q2: 4,298,248 shares 4,298,248$30.5M1.47%+4,068,384Timeline
TYRATYRA BIOSCIENCES INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q3: not reported; 2024Q4: not reported; 2025Q1: 25,000 shares; 2025Q2: 189,950 shares; 2025Q3: 696,825 shares; 2025Q4: 944,257 shares; 2026Q1: 1,276,968 shares; 2026Q2: 806,986 shares 806,986$25.8M1.24%-469,982Timeline
IRDOPUS GENETICS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q3: not reported; 2024Q4: not reported; 2025Q1: not reported; 2025Q2: not reported; 2025Q3: not reported; 2025Q4: not reported; 2026Q1: 6,075,028 shares; 2026Q2: 6,077,084 shares 6,077,084$25M1.21%+2,056Timeline
ANIKANIKA THERAPEUTICS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q3: 1,435,130 shares; 2024Q4: 1,435,130 shares; 2025Q1: 1,435,130 shares; 2025Q2: 1,435,130 shares; 2025Q3: 1,435,130 shares; 2025Q4: 1,435,130 shares; 2026Q1: 1,435,130 shares; 2026Q2: 1,435,130 shares 1,435,130$21M1.01%0Timeline
SGMTSAGIMET BIOSCIENCES INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q3: not reported; 2024Q4: not reported; 2025Q1: not reported; 2025Q2: not reported; 2025Q3: not reported; 2025Q4: not reported; 2026Q1: not reported; 2026Q2: 2,500,000 shares 2,500,000$19.3M0.93%newTimeline
ARTVARTIVA BIOTHERAPEUTICS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q3: not reported; 2024Q4: not reported; 2025Q1: not reported; 2025Q2: not reported; 2025Q3: not reported; 2025Q4: not reported; 2026Q1: not reported; 2026Q2: 1,736,111 shares 1,736,111$16.8M0.81%newTimeline
FTHFAETH THERAPEUTICS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q3: not reported; 2024Q4: not reported; 2025Q1: not reported; 2025Q2: not reported; 2025Q3: not reported; 2025Q4: not reported; 2026Q1: 126,002 shares; 2026Q2: 629,467 shares 629,467$15.7M0.76%+503,465Timeline
MBXMBX BIOSCIENCES INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q3: not reported; 2024Q4: not reported; 2025Q1: not reported; 2025Q2: not reported; 2025Q3: not reported; 2025Q4: not reported; 2026Q1: 848,590 shares; 2026Q2: 200,000 shares 200,000$11M0.53%-648,590Timeline
VRCAVERRICA PHARMACEUTICALS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q3: not reported; 2024Q4: not reported; 2025Q1: not reported; 2025Q2: not reported; 2025Q3: 923,910 shares; 2025Q4: 923,910 shares; 2026Q1: 923,910 shares; 2026Q2: 923,910 shares 923,910$5.65M0.27%0Timeline
CLRBCELLECTAR BIOSCIENCES INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q3: not reported; 2024Q4: not reported; 2025Q1: not reported; 2025Q2: not reported; 2025Q3: not reported; 2025Q4: not reported; 2026Q1: not reported; 2026Q2: 469,998 shares 469,998$1.31M0.06%newTimeline

Options

Puts and calls, as filed. The amount and value describe the underlying shares, not the option premium, so they stay out of % of portfolio (H5).

SecurityTypeAmountValueChange
RVMDREVOLUTION MEDICINES INC Stockcall251,800$47.2M+22,900
AGIOAGIOS PHARMACEUTICALS INC COMcall90,000$3.34M0
ADMAADMA BIOLOGICS INC COMcall300,000$2.51M0

Sold out in Q2 2026

Positions in the previous quarter's report that this quarter's report no longer lists.

SecurityShares beforeValue beforeType
MLYSMINERALYS THERAPEUTICS INC2,772,654$75.1Mshares
CGONCG ONCOLOGY INC900,000$60.9Mcall
SYRESPYRE THERAPEUTICS INC878,127$44.3Mshares
MAZEMAZE THERAPEUTICS INC614,962$18.4Mshares
XLOXILIO THERAPEUTICS INC112,128$943Kshares

How Q2 2026 was built

Available 13F filings of this filer for the quarter and their roles: the base report is the latest original or restatement, NEW HOLDINGS amendments filed after it are added (method).

FilingRoleAmendmentFiledAcceptedIngested
13F-HR 0001420506-26-001809 base2026-08-14acceptance time not in the bulk data set

Filings

Every filing of this filer: 13F reports and notices, the 13D and 13G it filed or is a reporting person of, and Forms 3, 4 and 5 it reported as an owner.

FilingSubjectFiledAcceptedIngested
13F-HR 0001420506-26-001809 Quarter ended 2026-06-302026-08-14acceptance time not in the bulk data set
13F-HR 0001420506-26-001039 Quarter ended 2026-03-312026-05-15acceptance time not in the bulk data set
13F-HR 0001420506-26-000584 Quarter ended 2025-12-312026-02-17acceptance time not in the bulk data set
13F-HR 0001420506-25-003441 Quarter ended 2025-09-302025-11-14acceptance time not in the bulk data set
13F-HR 0001420506-25-002188 Quarter ended 2025-06-302025-08-14acceptance time not in the bulk data set
13F-HR 0001420506-25-001290 Quarter ended 2025-03-312025-05-15acceptance time not in the bulk data set
13F-HR 0001420506-25-000624 Quarter ended 2024-12-312025-02-14acceptance time not in the bulk data set
13F-HR 0001420506-24-002574 Quarter ended 2024-09-302024-11-14acceptance time not in the bulk data set
13F-HR 0001814554-24-000010 Quarter ended 2024-06-302024-08-14acceptance time not in the bulk data set
13F-HR 0001727492-24-000006 Quarter ended 2024-03-312024-05-13acceptance time not in the bulk data set
13F-HR 0001727492-24-000002 Quarter ended 2023-12-312024-02-14acceptance time not in the bulk data set
13F-HR 0001727492-23-000011 Quarter ended 2023-09-302023-11-14acceptance time not in the bulk data set
13F-HR 0001727492-23-000009 Quarter ended 2023-06-302023-08-14acceptance time not in the bulk data set
13F-HR 0001814554-23-000002 Quarter ended 2023-03-312023-05-15acceptance time not in the bulk data set
13F-HR/A 0001814554-23-000005 Quarter ended 2022-12-312023-05-15acceptance time not in the bulk data set
13F-HR 0001727492-23-000005 Quarter ended 2022-12-312023-02-15acceptance time not in the bulk data set